Commercial kitchen service group(LON:FLTA ) a reported FY19 revenue increase of 75% to £24.9m for the 12 months to 31 December 2019, up from £14.2m.
The group said the surge in revenue was largely driven by a £8.6m or 34% from a full 12 months contribution from environmental services firm, Watbio, which the company acquired in December 2018. Meanwhile, organic revenue growth for the period was 16%.
Adjusted EBITDA increased 20% to £3.2m reflecting the increased overheads from the full year spending impact of Watbio.
Adjusted Profit before tax, excluding non-cash charges (amortization, depreciation and share based payments) therefore increased 7% to £2.6m from 2.4m in 2018.
Despite moving into a FY19 net debt position of £2.1m from a net cash position of £2.1m for FY18, the group said it remains ‘in a strong position’ and expects revenues and margins to return to the levels seen in the first quarter following the easing of the lockdown period.
Shares in Filta Group Holdings were trading 4.69% higher at 111.5p on Thursday morning.
Jason Sayers, CEO of Filta Group said “ the acquisition of Watbio has established the group as a leading provider of grease management services in the UK with room for further growth.
"We also saw some good performances from our other company-owned businesses in the UK, where revenue grew by 18% and in North America, where revenue was up by 23%,” he said.
During the lockdown period and in response to requests, the group has launched a new sanitising service, FiltaShield, which can protect against Covid-19 for up to 30 days.
FiltaShield was launched in the UK in April as a direct service to the group’s existing customers and to any others which have to ensure safety for their staff and customers.
The group said the service is being provided in North America through its franchise network and that it will potentially look to do the same in Europe.
The company added that it was not recommending the payment of a final dividend in light of the uncertainty surrounding Covid-19.
"Our long-term focus remains on growing the business both organically and through acquisitions of high margin, repeat revenue businesses in the grease management market,” added Sayers.
Follow News & Updates fromhere:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
Majid Shafiq, CEO of i3 Energy (AIM:I3E), and CFO, Graham Heath, discuss today’s follow-on deal to sell the Gain assets to Harvard Resources which will occur following the completion of the group’s previously announced C$80 million reverse takeover .
i3 Energy plc, an independent oil and gas company with assets and operations in the UK, Final Results for the year ended 31 December 2019 show significant operational progress for the pre-revenue company with net loss of £10.8m. To fund the Gain acquisition announced post period end in 2020, i3 is proposing to raise £30 million at a price of 5 pence per share, an 18% discount to the closing mid-price at which i3's shares suspended on 23 June 2020.
Oilex, the Operator of the PSC and on behalf of the JDPA joint venture, has reached amicable settlement with JPDA in East Timor with a settlement of US$0.8m payable in 2021 and 2022 financial years. The settlement amount is fully provided for in the FY19 accounts.
Avacta Group has entered into a collaboration with the Liverpool School of Tropical Medicine to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing in conjunction with Cytiva.
Shield Therapeutics said a reanalysis of the AEGIS-H2H study for its iron deficiency lead product Feraccru®/Accrufer® has confirmed the product as a credible alternative to IV therapy for patients with iron deficiency anaemia.